Literature DB >> 24585182

Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment.

Sarah J Hardcastle1, Ellen Legge, Chris S Laundy, Sarah J Egan, Rosemary French, Gerald F Watts, Martin S Hagger.   

Abstract

BACKGROUND: Familial hypercholesterolemia (FH) is a serious genetic disorder affecting approximately 1 in every 300 to 500 individuals and is characterised by excessively high low-density lipoprotein (LDL) cholesterol levels, substantially increased risk of early-onset coronary heart disease (CHD) and premature mortality. If FH is untreated, it leads to a greater than 50 % risk of CHD in men by the age of 50 and at least 30 % in women by the age of 60. FH can be diagnosed through genetic screening and effectively managed through pharmacological treatment and lifestyle changes.
PURPOSE: Familial hypercholesterolemia (FH) is a genetic health condition that increases the risk of cardiovascular disease. Although FH can be effectively managed with appropriate pharmacological and dietary interventions, FH detection rate through genetic screening remains low. The present study explored perceptions and experiences of FH patients (N = 18) involved in a genetic cascade screening programme.
METHODS: Face-to-face interviews were conducted to assess patients' knowledge and understanding of FH, explore factors linked to adherence to health-protective behaviours and examine perceptions of genetic screening.
RESULTS: Thematic analysis of interviews revealed four themes: disease knowledge, severity of FH, lifestyle behavioural change and barriers to cascade screening and treatment. Participants recognised FH as a permanent, genetic condition that increased their risk of CHD and premature mortality. Many participants dismissed the seriousness of FH and the importance of lifestyle changes because they perceived it to be effectively managed through medication. Despite positive attitudes toward screening, many participants reported that relatives were reluctant to attend screening due to their relatives' 'fatalistic' outlook or low motivation. Participants believed that they had insufficient authority or control to persuade family members to attend screening and welcomed greater hospital assistance for contact with relatives.
CONCLUSIONS: Findings support the adoption of direct methods of recruitment to cascade screening led by medical professionals, who were perceived as having greater authority. Other implications included the need for clinicians to provide clear information, particularly to those who are asymptomatic, related to the seriousness of FH and the necessity for adherence to medication and lifestyle changes.

Entities:  

Mesh:

Year:  2015        PMID: 24585182     DOI: 10.1007/s12529-014-9402-x

Source DB:  PubMed          Journal:  Int J Behav Med        ISSN: 1070-5503


  30 in total

1.  Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information.

Authors:  N Hallowell; C Foster; R Eeles; A Ardern-Jones; V Murday; M Watson
Journal:  J Med Ethics       Date:  2003-04       Impact factor: 2.903

Review 2.  Using the experiences of people with familial hypercholesterolaemia to help reduce the risk of cardiovascular disease: a qualitative systematic review.

Authors:  Lauretta A Muir; Peter M George; Lisa Whitehead
Journal:  J Adv Nurs       Date:  2012-02-20       Impact factor: 3.187

3.  Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.

Authors:  Dalya Marks; David Wonderling; Margaret Thorogood; Helen Lambert; Steve E Humphries; H Andrew W Neil
Journal:  BMJ       Date:  2002-06-01

4.  Making sense of risk: an interpretative phenomenological analysis of vulnerability to heart disease.

Authors:  Victoria Senior; Jonathan A Smith; Susan Michie; Theresa M Marteau
Journal:  J Health Psychol       Date:  2002-03

5.  Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes.

Authors:  Roeland Huijgen; Maud N Vissers; Iris Kindt; Mieke D Trip; Eric de Groot; John J P Kastelein; Barbara A Hutten
Journal:  Circ Cardiovasc Genet       Date:  2011-06-04

6.  Screening for familial hypercholesterolaemia in relatives.

Authors:  S Tonstad; L E Vollebaek; L Ose
Journal:  Lancet       Date:  1995-11-25       Impact factor: 79.321

7.  Will genetic testing for predisposition for disease result in fatalism? A qualitative study of parents responses to neonatal screening for familial hypercholesterolaemia.

Authors:  V Senior; T M Marteau; T J Peters
Journal:  Soc Sci Med       Date:  1999-06       Impact factor: 4.634

8.  Risk perception of participants in a family-based genetic screening program on familial hypercholesterolemia.

Authors:  M C van Maarle; M E A Stouthard; G J Bonsel
Journal:  Am J Med Genet A       Date:  2003-01-15       Impact factor: 2.802

9.  How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia? Psychological impact and screenees' views.

Authors:  M C van Maarle; M E A Stouthard; P J Marang-van de Mheen; N S Klazinga; G J Bonsel
Journal:  Community Genet       Date:  2001

Review 10.  Familial hypercholesterolemia from children to adults.

Authors:  Leiv Ose
Journal:  Cardiovasc Drugs Ther       Date:  2002-07       Impact factor: 3.727

View more
  21 in total

Review 1.  Barriers and facilitators for cascade testing in genetic conditions: a systematic review.

Authors:  Swetha Srinivasan; Nae Yeon Won; W David Dotson; Sarah T Wright; Megan C Roberts
Journal:  Eur J Hum Genet       Date:  2020-09-18       Impact factor: 4.246

2.  Larger and More Prominent Graphic Health Warnings on Plain-Packaged Tobacco Products and Avoidant Responses in Current Smokers: a Qualitative Study.

Authors:  Sarah J Hardcastle; Derwin C K Chan; Kim M Caudwell; Sarwat Sultan; Jo Cranwell; Nikos L D Chatzisarantis; Martin S Hagger
Journal:  Int J Behav Med       Date:  2016-02

Review 3.  Prevention of rheumatic diseases: strategies, caveats, and future directions.

Authors:  Axel Finckh; Kevin D Deane
Journal:  Rheum Dis Clin North Am       Date:  2014-09-04       Impact factor: 2.670

4.  A qualitative study of patients' perceptions of the value of molecular diagnosis for familial hypercholesterolemia (FH).

Authors:  Nina Hallowell; Nicholas Jenkins; Margaret Douglas; Simon Walker; Robert Finnie; Mary Porteous; Julia Lawton
Journal:  J Community Genet       Date:  2016-11-19

5.  Motivation, Perception, and Treatment Beliefs in the Myocardial Infarction Genes (MI-GENES) Randomized Clinical Trial.

Authors:  Sharma Kattel; Tochukwu Onyekwelu; Sherry-Ann Brown; Hayan Jouni; Erin Austin; Iftikhar J Kullo
Journal:  J Genet Couns       Date:  2017-04-06       Impact factor: 2.537

Review 6.  Knowns and unknowns in the care of pediatric familial hypercholesterolemia.

Authors:  Andrew C Martin; Samuel S Gidding; Albert Wiegman; Gerald F Watts
Journal:  J Lipid Res       Date:  2017-07-12       Impact factor: 5.922

7.  Predicting Self-Management Behaviors in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of Beliefs About Illnesses and Beliefs About Behaviors.

Authors:  Martin S Hagger; Sarah J Hardcastle; Catherine Hingley; Ella Strickland; Jing Pang; Gerald F Watts
Journal:  Int J Behav Med       Date:  2016-06

8.  Treatment decision making for adolescents with familial hypercholesterolemia: Role of family history and past experiences.

Authors:  Thomas I Mackie; Lisa L Tse; Sarah D de Ferranti; Heather R Ryan; Laurel K Leslie
Journal:  J Clin Lipidol       Date:  2015-05-07       Impact factor: 4.766

Review 9.  My Approach to the Patient With Familial Hypercholesterolemia.

Authors:  Maya S Safarova; Iftikhar J Kullo
Journal:  Mayo Clin Proc       Date:  2016-06       Impact factor: 7.616

10.  Improving detection and management of familial hypercholesterolaemia in Australian general practice.

Authors:  Tom Brett; Dick C Chan; Jan Radford; Clare Heal; Gerard Gill; Charlotte Hespe; Cristian Vargas-Garcia; Carmen Condon; Barbara Sheil; Ian W Li; David R Sullivan; Alistair W Vickery; Jing Pang; Diane E Arnold-Reed; Gerald F Watts
Journal:  Heart       Date:  2021-05-20       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.